Acanthoside B (oral gavage; 10-20 mg/kg; 7 days prior to Scopolamine injection) attenuates Scopolamine inflicted AD-like amnesic traits by restoring the cholinergic activity, decreasing the endogenous antioxidant status, suppressing neuroinflammation, and activating the TrkB/CREB/BDNF pathway in mice.